Professor, Juntendo University, School of Medicine;
President, Japan Endotoxin and Innate Immunity Society;
President, Society for Functional Food Research;
Former Executive Director, Japanese Society for Bacteriology;
Chairman, International Endotoxin and Innate Immunity Society (IEIIS2012) ;
Former Vice President, Japanese Society for Chitin and Chitosan
Director, Japanese Society for Medical Use of Functional Foods
Ryuji Kawaguchi, Ph.D.
CEO & President, PropGene Inc.;
Director, Health Care Technology Foundation (HECTEF);
Former Professor, Consolidated Research Institute for Advanced Scienceand Medical Care, Waseda University( ASMeW);
Former Professor, Gumma Paz College;
Council, The Japanese Society for Gene Diagnosis and Therapy
Tatsushi Gocho
Director, TechnoProducer Corporation; Associate Professor, Faculty of Intellectual Property,
Osaka Institute of Technology; Senior Patent Attorney, J.Z.M.C. Patent and Trademark Agency
Hiroshi TAMURA, Ph.D.
Hiroshi Tamura (born in October 1952, Japan) has been the owner/head of LPS (Laboratory Program Support) Consulting Office since February 2013. In addition, Tamura serves as an invited associate professor at the Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, and has received a Visiting Research Fellowship from the Tokyo University of Pharmacy and Life Science. Tamura has also served as executive director and head of the Secretariat of Japan Bio-Venture Development Association (JBDA) since June 2016, in addition to a senior advisor at Prop-Gene Inc., in Tokyo. Tamura graduated from Tohoku University in 1976 with a degree in gricultural/Food Chemistry, and obtained a master's degree two years later, after which he joined Seikagaku Corp. in Tokyo. Tamura also received a Ph.D. in Science and Engineering from Saitama University in 1997. It was while working for Seikagaku Corp. that Tamura and his colleagues pioneered an advanced chromogenic assay technology for bacterial endotoxin and paved the way for its standardized testing addressed in international pharmacopoeia. Furthermore, Tamura and his colleagues set out to develop an innovative diagnostic platforms for detecting endotoxemia from septic patients and/or invasive fungal iseases (IFD) based on horseshoe crab (LAL) coagulation systems. Then, Tamura and his colleagues made every efforts to engage in the transfer of pivotal LAL technologies to a subsidiary company (Associates of Cape Cod, Inc.) in Massachusetts, US. Tamura was also committed to help with obtaining FDA approval to launch a new in-vitro diagnostic test for IFD based on a clinical trial carried out in the US. Tamura has made major contributions to developing and improving LAL-base technologies to get the related products onto the market place with a number of scientific papers and patents. Tamura left the company in January 2012 and set up a consulting office in Tokyo in February 2013.
493f.png)
8de8.png)
8a7e.png)
